FDA Brief

Warning letters Biologics

FDA warning letter to

4U Health

High riskIssued Mar 17Posted Mar 24Center for Biologics Evaluation and Research (CBER)

FDA says 4U Health sells an unapproved HIV dried blood spot self-collection kit, making it adulterated and misbranded.

What happened

FDA reviewed 4U Health’s website in March 2026 and the firm’s April 30, 2025 response to an earlier FDA letter. FDA found the company offers an HIV serological diagnostic dried blood spot card self-collection kit to individuals for at-home sample collection and shipment to labs. FDA says the kit lacks approved premarket approval or an investigational device exemption and has not been cleared through 510(k) notification.

What FDA found

  1. The HIV DBS self-collection kit is a device offered without an approved premarket approval application or an approved investigational device exemption.

    FD&C Act section 501(f)(1)(B), 21 U.S.C. 351(f)(1)(B); section 515(a), 21 U.S.C. 360e(a); section 520(g), 21 U.S.C. 360j(g)
  2. The kit is misbranded because the firm did not provide FDA notification of intent to introduce it into commercial distribution as required by section 510(k).

    FD&C Act section 502(o), 21 U.S.C. 352(o); section 510(k), 21 U.S.C. 360(k)

What FDA wants

FDA asks 4U Health to immediately stop activities that adulterate or misbrand the kit and, within 15 working days of receipt, to send a written response describing corrective steps and how it will prevent recurrence.

Who should pay attention

  • companies selling at-home diagnostic collection kits
  • labs and telehealth services that order or process self-collected samples
  • distributors of specimen collection devices

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  4. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk